Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 45257U108 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. 13G/A | 17.4% |
8/14/2026
Event 6/30/2026
|
||
|
FMR LLC
13G/A
|
15.0% |
10/7/2025
Event 9/30/2025
|
||
| FMR LLC | 15.0% | |||
| Abigail P. Johnson | 15.0% | |||
|
Immunome Aggregator, LP
13D/A
|
6.0% |
2/4/2025
Event 1/31/2025
|
||
| Immunome Aggregator, LP | 6.0% | |||
| Enavate Sciences GP, LLC | 6.0% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (7) | ||||
|
Redmile Group, LLC
13G/A
|
4.9% |
5/15/2026
Event 3/31/2026
|
||
| Redmile Group, LLC | 4.9% | |||
| Jeremy C. Green | 4.9% | |||
|
EcoR1 Capital, LLC
13G/A
|
4.7% |
5/15/2025
Event 3/31/2025
|
||
| EcoR1 Capital, LLC | 4.7% | |||
| Oleg Nodelman | 4.7% | |||
| EcoR1 Capital Fund Qualified, L.P. | 4.4% | |||
|
Sirenia Capital Management LP
13G/A
|
4.3% |
8/14/2026
Event 6/30/2026
|
||
| Sirenia Capital Management LP | 4.3% | |||
| Alex Silverstein | 4.3% | |||
|
Enavate Sciences GP, LLC
13D/A
|
4.3% |
12/22/2025
Event 12/18/2025
|
||
| Enavate Sciences GP, LLC | 4.3% | |||
| Immunome Aggregator, LP | 4.3% | |||
| Janus Henderson Group PLC 13G/A | 2.2% |
5/14/2025
Event 3/31/2025
|
||
|
Point72 Asset Management, L.P.
13G/A
|
0% |
5/15/2026
Event 3/31/2026
|
||
| Point72 Asset Management, L.P. | 0% | |||
| Point72 Capital Advisors, Inc. | 0% | |||
| Steven A. Cohen | 0% | |||
| Vanguard Group Inc 13G/A | 0% |
3/26/2026
Event 3/13/2026
|
||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 4 | 5.48 k | $118 k |
| 2026 Q2 | 210 | 120 M | $2.61 B |
| 2026 Q1 | 209 | 117 M | $2.54 B |
| 2025 Q4 | 199 | 120 M | $2.57 B |
| 2025 Q3 | 164 | 91.4 M | $1.07 B |
| 2025 Q2 | 150 | 81.5 M | $758 M |
| 2025 Q1 | 152 | 77.0 M | $519 M |
| 2024 Q4 | 127 | 53.3 M | $566 M |
| 2024 Q3 | 124 | 51.7 M | $751 M |
| 2024 Q2 | 123 | 48.8 M | $591 M |
| 2024 Q1 | 113 | 37.5 M | $926 M |
| 2023 Q4 | 64 | 21.7 M | $232 M |
| 2023 Q3 | 42 | 3.10 M | $25.8 M |
| 2023 Q2 | 44 | 2.32 M | $18.3 M |
| 2023 Q1 | 34 | 1.86 M | $9.34 M |
| 2022 Q4 | 30 | 2.13 M | $4.91 M |
| 2022 Q3 | 27 | 2.39 M | $10.7 M |
| 2022 Q2 | 28 | 2.41 M | $7.78 M |
| 2022 Q1 | 34 | 3.44 M | $19.8 M |
| 2021 Q4 | 38 | 2.86 M | $37.2 M |
| 2021 Q3 | 40 | 2.39 M | $58.3 M |
| 2021 Q2 | 30 | 2.38 M | $41.1 M |
| 2021 Q1 | 32 | 1.91 M | $64.7 M |
| 2020 Q4 | 27 | 2.08 M | $20.1 M |